John Docherty
President and Head of Research at Lexaria Bioscience | Greater Toronto Area, Canada
John Docherty’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Principal at Docherty Management Limited in April 2013 - Present
President and Head of Research at Lexaria Bioscience in April 2015 - Present
President & Chief Operating Officer at Helix BioPharma Corporation in November 2007 - December 2013
President at Pharmaderm Laboratories Ltd. in June 2004 - July 2008
Vice President, Corporate Development at Helix BioPharma Corp. in September 1999 - October 2007
Management Consultant at PriceWaterhouseCoopers Canada in January 1998 - August 1999
US Regulatory Affairs Associate at Nu-Pharm Inc. (A division of Apotex) in January 1996 - December 1997
Regulatory Affairs Associate at Astra Pharmaceuticals in November 1994 - November 1995
University of Toronto, January 1993 to January 1995
University of Toronto at Mississauga - Erindale College, January 1989 to January 1993
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
Discover more about Lexaria Bioscience
Head Of Legal Department at Lexaria Bioscience
Trademark Agent at Montgomery Miles & Stone Law Firm
(January 2018 – Present)
Financial Controller
Financial Controller at Lexaria Bioscience
(September 2021 – Present)
Head Pharmaceutical Research Scientist
Head Pharmaceutical Research Scientist at Lexaria Bioscience
(October 2020 – Present)
Head of Investor Relations
• Developed and implemented a proactive investor relations strategy and program, ensuring that the company's business strategy and progress was clearly communicated to the general public
• A key spokesperson to the investment community with the role of educating and persua...
Chief Executive Officer | BOD Member at Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a global innovator in drug delivery platforms. It's patented drug delivery formulation and processing technology, DehydraTECH, improves the way in which active pharmaceutical ingredients enter the bloodstream. Lexaria is currently f...
Chief Financial Officer, Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a broad range of active pharmaceutical ingredients ("APIs”) using our patented DehydraTECH drug delivery-enabling platform technology. Our current focus is the investig...
What is John Docherty email address?
Email John Docherty at [email protected]. This email is the most updated John Docherty's email found in 2026.
How to contact John Docherty?
To contact John Docherty send an email to [email protected].
What company does John Docherty work for?
John Docherty works for Lexaria Bioscience.
What is John Docherty's role at Lexaria Bioscience?
John Docherty is President and Head of Research
What industry does John Docherty work in?
John Docherty works in the Consumer Goods industry.
